GO
Loading...

Pharmaceuticals

More

  • As I begin my vacation, I wanted to tell you about a story I did that's airing while I'm away on the new edition of CNBC's "Business Nation" this Wednesday (November 7th) at 9 p and midnight ET. It's about the increasingly strained relationship between drug sales reps and doctors.

  • Pharma Stocks To Watch On Monday (And My Time Off) Sunday, 4 Nov 2007 | 12:57 PM ET

    I'm taking some much needed time off for a couple of weeks. Actually, our scheduling guru at CNBC, Alex Crippen, told me if I don't use all of the days I've accumulated by the end of next month, I'll lose them. I consider myself a hard worker, but I'm not that generous. So, off I go.

  • Vertex In The "Vortex" Over Hepatitis C Test Results Friday, 2 Nov 2007 | 12:04 PM ET
    Vertex

    There's a flurry of selling going on this morning in shares of the biopharma Vertex Pharmaceuticals. Overnight the embargo lifted on the long awaited results of the company's mid-stage test on a new type of Hepatitis C drug. Two studies show that six months out 60% and 65% of patients had no detectable virus in their blood.

  • Zocor

    This morning we got more evidence about the havoc generic Zocor is wreaking on all of the companies that make brand-name statins--the pills to fight cholesterol. AstraZeneca is the latest casualty. On a down day in the markets AZN is one of the biggest losers in the sector.

  • Shire's Third-Quarter Earnings Top Forecast Thursday, 1 Nov 2007 | 10:46 AM ET

    Britain's Shire beat forecasts with a 32 percent rise in third-quarter underlying earnings on Thursday and said its new hyperactivity drug, Vyvanse, had been well received by doctors and patients.

  • Genentech's Avastin: An "Eye Opening" Disclosure? Thursday, 1 Nov 2007 | 9:44 AM ET

    Yet another chapter in the unfolding saga of Genentech's Avastin being used instead of Lucentis to treat age-related macular degeneration (AMD). The other day I blogged about the new "Open Letter" on the company's homepage announcing that it's delaying the implementation of its attempted crackdown on the cheaper, similar cancer drug being used...

  • AmerisourceBergen Quarterly Earnings Tumbles 28% Thursday, 1 Nov 2007 | 8:28 AM ET

    AmerisourceBergen, one of the top U.S. drug wholesalers, said Thursday that quarterly earnings fell 28 percent as it took a write-down on its tetanus-diphtheria vaccine inventory.

  • Crestor Competition Overshadows AstraZeneca Results Thursday, 1 Nov 2007 | 8:11 AM ET

    AstraZeneca profits fell 14 percent in the third quarter, hit by competition from cheap generics plus acquisition and restructuring charges, the Anglo-Swedish drugmaker said on Thursday.

  • On the Line: Nastech Pharma CEO Dr. Stephen Quay Wednesday, 31 Oct 2007 | 8:02 PM ET

    The chief executive talks up his approach to business, a pesky payment owed by Procter & Gamble and why the company will succeed where rivals have failed.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Eli Lilly: Will They Get Lucky With 'One A Day' Cialis? Wednesday, 31 Oct 2007 | 3:36 PM ET
    Eli Lilly

    Today's the day Eli Lilly was expected to get a Food and Drug Administration decision on the first-ever one-a-day impotence drug. Right now, the company sells Cialis for use as needed. But men could pop this one every day--like an aspirin or multi-vitamin--so the drug would always be "on boa

  • Amylin's Once A Week Byetta: Good Is Not Enough Wednesday, 31 Oct 2007 | 12:21 PM ET
    Byetta Needle

    This morning Amylin Pharmaceuticals, Eli Lilly and Alkermes announced the highly anticipated test results on their once-a-week, Type 2 diabetes drug. One analyst recently called this the most important biotech data of the second half of this year. Many expect the drug to become a multi-billion dollar blockbuster.

  • McKesson Shares Surge on Strong Earnings Wednesday, 31 Oct 2007 | 11:38 AM ET

    Shares of McKesson jumped to their highest price since 1999 on Wednesday, the day after the drug wholesaler posted better-than-expected quarterly results and raised its outlook for the full year.

  • Sanofi Raises Outlook on Strong Third-Quarter Profit Wednesday, 31 Oct 2007 | 5:39 AM ET

    French drugmaker Sanofi-Aventis raised its full-year 2007 outlook on Wednesday as it reported a forecast-beating 9.1 percent rise in third-quarter profit, helped notably by vaccines and cost cuts.

  • McKesson Profit Rises 8%; Company Boosts Outlook Tuesday, 30 Oct 2007 | 5:16 PM ET
    McKesson

    Pharmaceutical wholesaler McKesson  reported that its quarterly profit rose a better-than-expected 8 percent, led by increased demand for its drug distribution business, and the company raised its full-year earnings forecast.

  • Genentech "Sees The Light" On Avastin? Tuesday, 30 Oct 2007 | 1:05 PM ET

    In a remarkably candid "Open Letter" on the homepage of its web site Genentech is taking a step back from implementing its new restrictive policy over the use of the cancer drug Avastin in lieu of Lucentis for age-related macular degeneration (AMD), the leading cause of adult blindness. I had recently blogged about the company's action and angry reader response to it.

  • ASCO: 'Open Door Policy' Levels Playing Field Monday, 29 Oct 2007 | 3:37 PM ET

    TheStreet.com's senior biotech writer Adam Feuerstein broke this story earlier today, but now we've confirmed it independently. The American Society of Clinical Oncology (ASCO) is changing its ways.

  • Lipitor

    Pfizer has been using Dr. Robert Jarvik, the inventor of the Jarvik Artificial Heart, for quite some time now as its Lipitor "celebrity" pitchman. But recently I've noticed something remarkable creeping into his copy--the script he reads for TV and radio spots and the text that appears in the print ads.

  • Merck, Sanofi, Glaxo Get "Shot In The Arm" From U.K. Friday, 26 Oct 2007 | 12:52 PM ET

    British health authorities today announced that starting next fall, all 12- and 13-year-old girls will have to get the controversial shots to prevent the sexually transmitted virus that can lead to cervical cancer. Merck and Sanofi-Aventis are partners on the vaccine Gardasil and the UK-based GlaxoSmithKline makes a similar one Cervarix.

  • Eli Lilly: "Bloom" Is Off The Pipeline Thursday, 25 Oct 2007 | 11:43 AM ET
    Eli Lilly

    If the stock closes down at least 4.46% today (as I write this it is off nearly 7%) Eli Lilly will suffer its worst one-day loss in more than four years, according to our resident statistical expert Robert Hum. If it were to close off more than 7.79%, Hum says it would be the stock's biggest one-day fall since Oct. 23, 2002--almost five years to the day.

  • Health Care Stocks to Watch Thursday, 25 Oct 2007 | 10:55 AM ET

    Even as much of the economy contracts, health care continues to grow, and investment opportunities continue to grow with it. What to choose among those investment opportunities? Analyst Michael Magiera of Manning & Napier looks past some of the more volatile pharmaceutical stocks.